The Pharma Data

MARCH 8, 2021

Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. We are excited to be part of the Lyme disease vaccine development program with Valneva. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

APRIL 26, 2022

NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Drug Target Review

JANUARY 26, 2024

The level of human ACE2 protein produced by the cells was generally proportional to the number of ACE2 gene copies integrated into the mouse genome. Several of the mouse cell clones produced about 50 times more ACE2 than is normally present on mouse cells.

Production 114

Production DNA Virus Protein Expression 114

Broad Institute

SEPTEMBER 26, 2024

Additionally, astrocyte inflammation has been observed in patients with many neurodegenerative diseases. Preliminary western blot and immunofluorescence assays for protein expression reflected the presence of aged phenotypes, including decreased expression of Lap2β and H3K9me3, in hiPSC-astrocytes treated with the senescence cocktail.

Small Molecule 52

Small Molecule Protein Expression Disease Science 52

The Pharma Data

APRIL 8, 2021

OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs). Following U.S.

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

Therapies 59

Therapies RNA Protein Expression DNA 59

The Pharma Data

SEPTEMBER 10, 2020

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study. About multiple sclerosis Multiple sclerosis (MS) is a chronic disease that affects nearly 1 million people in the U.S.

Treatment 52

Treatment Disease FDA Approval Clinical Trials 52

The Pharma Data

APRIL 27, 2022

Up to half of all patients with breast cancer have tumours with a HER2 immunohistochemistry (IHC) score of 1+, or 2+ in combination with a negative in-situ hybridisation (ISH) test, a level of HER2 expression not currently eligible for HER2-targeted therapy. 1-4 Low HER2 expression occurs in both HR-positive and HR-negative disease.

Therapies 52

Therapies Trials Protein Expression Treatment 52

The Pharma Data

JUNE 7, 2023

Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. months (95% CI: 6.8-11.8)

Trials 40

Trials Protein Expression Therapies Treatment 40

The Pharma Data

AUGUST 16, 2021

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

SEPTEMBER 8, 2020

OCREVUS CHIMES study exclusively focused on disease insights and more tailored care for minority populations with MS. We remain committed to advancing the science in MS by investigating potential new medicines such as fenebrutinib, with the ultimate goal of halting progression of this disease,” said Levi Garraway, M.D.,

Clinical Trials 52

Clinical Trials Trials Disease FDA Approval 52

Alta Sciences

APRIL 17, 2024

Gene Therapy Gene therapy is currently considered for diseases, often rare, that have no other cures. We have conducted over 130 in-life studies in the last five years (over 95% conducted in NHPs), including IND-enabling studies for rare diseases and CRISPR gene editing therapeutics in NHPs.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

AUGUST 9, 2021

The safety profile of Enhertu was consistent with previous clinical trials, with no new safety concerns identified and no Grade 4 or 5 treatment-related interstitial lung disease events. The data will be presented at an upcoming medical meeting and shared with health authorities. AstraZeneca with MSD (Merck & Co.,

Trials 52

Trials Treatment Clinical Trials Protein Expression 52

The Pharma Data

JANUARY 15, 2021

“Patients with metastatic HER2 positive gastric cancer with progression following first-line treatment have historically faced poor outcomes, including low response to treatment and rapid disease progression,” said Ronan Kelly, MD, MBA, Director of the Charles A. mg/kg, interstitial lung disease occurred in 10% of patients. Caruth, Jr.

Treatment 52

Treatment Trials Disease Therapies 52

The Pharma Data

JANUARY 13, 2021

Sepofarsen has been granted orphan drug designation in the United States and the European Union and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the PRIME scheme by the EMA. Patients with severe COVID-19 infection often present with acute severe inflammation and organ failure.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

Broad Institute

OCTOBER 4, 2023

Related links Merkin Prize Inaugural Merkin Prize in Biomedical Technology awarded to Dr. As reported last year in ACS Chemical Biology , Wang’s lab developed a way to construct messenger-oligonucleotide conjugated RNAs with chemically modified tails, a strategy that reduced RNA degradation while increasing therapeutic protein expression in cells.

DNA 52

DNA RNA Science Protein Expression 52

The Pharma Data

OCTOBER 28, 2020

Preliminary results from the first five patients treated indicate substantial improvements in all patients in at least two disease domains including communication, behavior, sleep, gross motor function, and fine motor function as measured by the Clinical Global Impression of Improvement Scale for Angelman Syndrome (CGI-I-AS) at day 128.

Protein Expression 40

Protein Expression Therapies Treatment Disease 40

The Anticancer Fund

SEPTEMBER 29, 2021

Please get in touch if you’re interested in discussing research based on the findings presented below ( info@anticancerfund.org ). This drug combination is rationally designed to target multiple escape mechanisms by which refractory disease evades treatment. Patients received celecoxib, 400 mg, or placebo, once daily for 2 years.

Clinical Trials 40

Clinical Trials Drugs Trials Protein Expression 40

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. Key findings of the trial: .

Vaccine 40

Vaccine Trials Treatment Virus 40